Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review (Business Wire)
UF Innovate | Sid Martin alumni startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), announced it has resumed its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential treatment of OM following a positive review by an independent […]
Oragenics Touts New Drug to Fight Clostridium Difficile (Proactive Investors)
New research by Sid Martin Biotech alum Oragenics Inc., now a Tampa-based clinical-stage biotech group, has uncovered a novel type of antibiotic known as a lantibiotic for the treatment of clostridium difficile, an infection causing colitis, called OG716. When golden Syrian hamsters infected with clostridium difficile were treated with the drug OG716, a variant of […]